Results 111 to 120 of about 74,341 (223)

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors

, 2011
Just over a decade ago, gastrointestinal tumours were a poorly understood mesenchymal neoplasm unsuccessfully treated with chemotherapy. Cytotoxic therapy for advanced disease yielded response rates of 10% and median survival of just 18 months.
Doran Ksienski
core   +1 more source

Protein Lactylation in Cancer: From Mechanisms to Therapy

MedComm, Volume 7, Issue 11, November 2026.
Increased glycolysis and lactate accumulation promote histone and nonhistone protein lactylation, linking tumor metabolic reprogramming to treatment adaptation. Lactylation enhances DNA repair, suppresses antitumor immunity, strengthens antioxidant defenses, and facilitates cell‐cycle checkpoint escape, collectively promoting resistance to chemotherapy,
Wentian Huang, Ping Hu, Shun Wang, Xide Zhang, Ziran Ye, Shengqiang Chen, Fu Gao, Yuanyuan Chen, Yanyong Yang   +8 more
wiley   +1 more source

Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors

, 2007
PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the intestinal tract. Nearly all tumors express KIT protein, and most have an activating mutation in either KIT or PDGFRA.
DeSantis, D., Guo, T., Singer, S., Besmer, P., Antonescu, C. R., Maki, R. G., Agaram, N. P., Brennan, M. F., Socci, N. D., DeMatteo, R. P., Wong, G. C.   +10 more
core   +1 more source

Small‐Molecule Kinase Inhibitors Modulating Circadian Rhythms

Medicinal Research Reviews, Volume 46, Issue 6, Page 1735-1752, November 2026.
ABSTRACT The circadian clock mechanism generates 24‐h rhythms crucial for regulating various physiological processes, and its dysregulation has been implicated in numerous diseases. In cells, the circadian clock operates through a transcriptional‐translational feedback loop, where phosphorylation plays a pivotal role in maintaining accurate circadian ...
Irene Castellino, Manuela Bartolini, Rudolf Andrys, Kamil Musilek   +3 more
wiley   +1 more source

Interpretable Drug–Target Prediction via Geometric Alignment: A Linear Alternative to Deep Architectural Complexity

Molecular Informatics, Volume 45, Issue 11, November 2026.
The Multi‐View Linear Manifold (MVLM) aligns frozen chemical and protein language model embeddings in a shared geometric space using two linear projections. Binding is scored by a single dot product. MVLM achieves state‐of‐the‐art drug–target interaction prediction on KIBA, performs competitively on Davis, and recovers kinase phylogenetic structure ...
Aashutosh Ghimire, Chris Alvin, Adam Bess, Supratik Mukhopadhyay   +3 more
wiley   +1 more source

Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation

Respirology, Volume 31, Issue 11, Page 1077-1090, November 2026.
ABSTRACT Asthma is a heterogeneous syndrome featuring variable pathophysiology, clinical presentation and treatment response. This review examines a comprehensive endotype‐phenotype framework for asthma assessment with an emphasis on characteristics beyond T2 inflammatory status alone.
Mario Fernando, Gregory G. King
wiley   +1 more source

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia

, 2012
Yusuf Baran,1 Guray Saydam21Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey; 2Department of Hematology, School of Medicine, Ege University, Izmir, TurkeyAbstract: Chronic myeloid leukemia (CML) is a malignant ...
Saydam G, Baran Y
core  

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

, 2010
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease.
Daniels, Craig E, Mieras, Kathleen, Lasky, Joseph A, Limper, Andrew H, Imatinib-IPF Study Investigators, Gabor, Edith, Schroeder, Darrell R, Craig E. Daniels, Edith Gabor, Darrell R. Schroeder, Joseph A. Lasky, Kathleen Mieras, Andrew H. Limper   +12 more
core   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source